Last updated: July 12, 2026
Exelixis sued MSN Laboratories Private Limited in the District of Delaware on a Hatch-Waxman patent infringement theory tied to a generic ANDA filing. The case is docketed as Exelixis, Inc. v. MSN Laboratories Private Limited, 1:22-cv-00945. A complete litigation summary with claim-level holdings, asserted patent list, and procedural posture cannot be produced from the information provided.
What is Exelixis, Inc. v. MSN Laboratories Private Limited (1:22-cv-00945) about?
The caption identifies a patent infringement action brought by Exelixis against MSN Laboratories. The case number indicates a U.S. federal Hatch-Waxman-type dispute but does not specify:
- the asserted drug product and active ingredient,
- the ANDA sponsor reference listed drug,
- the Orange Book patents asserted,
- whether Exelixis alleged infringement under 35 U.S.C. § 271(e)(2) for an ANDA,
- or whether the matter includes counterclaims, stipulated dismissals, or a settlement.
Without the complaint, docket filings, or the patent list from the case record, no accurate infringement narrative, timeline, or IP analysis can be stated.
What litigation theories typically apply in Exelixis ANDA cases?
In Exelixis ANDA litigation, the usual framework is:
- 35 U.S.C. § 271(e)(2) (Hatch-Waxman “artificial” infringement tied to an ANDA filing),
- infringement of Orange Book-listed patents (composition, formulation, method of use, or manufacturing-related claims),
- and FDA approval-triggered remedies (injunctions or declaratory relief).
Those are structural possibilities, not a confirmed match for 1:22-cv-00945.
Which patents did Exelixis assert against MSN Laboratories in 1:22-cv-00945?
A correct answer requires the asserted patent numbers (and typically their listed expiration dates and assignees) from:
- the complaint,
- Exelixis’s infringement contentions,
- or the docket summary entries that enumerate patents.
Those details are not present in the prompt, so the asserted patent estate cannot be enumerated.
What patent families are commonly asserted by Exelixis in tyrosine kinase inhibitor portfolios?
Exelixis has historically asserted portfolios around:
- small-molecule kinase inhibitors,
- tablet/capsule formulation improvements,
- and method-of-use claims for oncology indications.
This is category-level background. It is not a patent-specific identification for this case.
What procedural milestones occurred in Exelixis v. MSN Laboratories Private Limited?
A litigation summary with analysis must track:
- complaint filing date,
- service and responsive pleadings,
- the court’s case management order,
- any motion to dismiss, transfer, or stay,
- claim construction schedule,
- trial or dispositive motion outcomes,
- and entry of final judgment, dismissal, or settlement.
Those milestones cannot be confirmed without the docket.
Typical Delaware Hatch-Waxman process (what to look for)
For ANDA patent cases in Delaware, the docket often includes:
- preliminary scheduling orders,
- infringement and invalidity contentions,
- Markman hearing scheduling for claim construction,
- summary judgment on patentability or non-infringement,
- and any Rule 54(b) or consent judgments following settlement.
No such events are provided in the input.
How strong is Exelixis’s patent estate in this case?
Patent strength analysis requires:
- asserted independent claim scope,
- claim construction outcomes (if any),
- the state of the patents (expired, granted, stayed, challenged, or lapsed),
- and known validity and infringement issues from the filings.
None of those specifics are available from the prompt.
Patent strength drivers for generic entry risk
In the absence of case-specific filings, only generic drivers can be listed:
- breadth of independent claims,
- remaining enforceable term,
- likelihood of design-around,
- whether patents are composition vs. method-of-use vs. formulation,
- and whether prior art challenges exist.
No case-level conclusions can be made.
Did MSN Laboratories file a Paragraph IV challenge or other ANDA certifications?
Whether MSN made a Paragraph IV certification (or other Paragraph IV-type notice) is determined by:
- the FDA ANDA status,
- Exelixis’s Orange Book enforcement allegations,
- and the notice of paragraph IV certification typically referenced in Hatch-Waxman complaints.
The prompt does not contain the drug name, ANDA number, or certifications.
How ANDA certification drives litigation posture
The certification type influences:
- whether Exelixis seeks an automatic 30-month stay,
- whether the case focuses on validity vs. non-infringement,
- and whether settlement timing coincides with regulatory milestones.
No such mapping can be performed for 1:22-cv-00945 without underlying FDA and complaint details.
What settlements or injunctions were reached, and when?
A real settlement analysis requires:
- settlement agreement terms (even high-level, such as effective dates and market-entry commitments),
- whether a stipulated dismissal was filed,
- whether a consent judgment or dismissal with prejudice occurred,
- and any covenants not to sue.
The prompt does not include any docket outcomes.
How does this case affect generic market entry for the challenged product?
To assess market-entry risk, the analysis must tie:
- the specific product and dosage forms,
- the expected approval and launch dates,
- the remaining patent and exclusivity timeline,
- and any agreed design-around or launch date restrictions.
None of these facts are provided.
Competitive landscape considerations
Generic entry risk is also driven by:
- other pending Paragraph IV challenges,
- co-litigants,
- and whether Exelixis’s portfolio is being asserted across multiple ANDAs.
This cannot be supported for this case without the case caption drug and docket context.
What is the Orange Book status of the asserted patents in 1:22-cv-00945?
Orange Book status requires:
- the reference listed drug,
- the Orange Book patent listing and expiration dates,
- and cross-referencing those to the patents asserted in the lawsuit.
No drug or patent list is provided.
Why Orange Book mapping matters
Orange Book status determines:
- whether the asserted patents are formulation vs. method vs. composition,
- whether they are listed for the exact NDA strength/dosage form,
- and the enforceability window used in settlement and injunction strategy.
No mapping can be produced.
Which jurisdictions are covered by the litigation and what is the likely remedy scope?
Patent infringement under § 271(e)(2) is adjudicated in U.S. federal court. The Delaware venue would govern:
- infringement and validity as to the asserted patents,
- injunctive or declaratory relief,
- and remedies available under Hatch-Waxman.
However, scope and remedy outcomes depend on claims and procedural outcomes that are not provided.
Key Takeaways
- Exelixis, Inc. v. MSN Laboratories Private Limited is docketed as 1:22-cv-00945 in the District of Delaware.
- The prompt does not include the asserted drug, asserted patents, ANDA number, Paragraph IV certifications, procedural milestones, or case outcome.
- Without those case-specific facts, no accurate litigation summary, patent list, strength analysis, or market-entry impact can be stated.
FAQs
- What court handled Exelixis v. MSN Laboratories Private Limited (1:22-cv-00945)?
- What does 1:22-cv-00945 indicate about the litigation type (ANDA vs. other IP claims)?
- How do Paragraph IV certifications typically shape Hatch-Waxman litigation posture?
- What documents in a Hatch-Waxman case disclose the asserted Orange Book patents?
- How is generic launch timing affected by settlement dismissals or consent judgments in Delaware?
References
No sources are cited because the prompt provides no case filings, docket entries, or patent/Orange Book data to cite.
